Attovia Therapeutics, Inc.

NASDAQ:ATTO

Biotechnology

Healthcare
$15.53 -1.20%

-$0.18 today

Market cap
$709.92M
Beta
0.00
P/E (TTM)
-15.9
EPS (TTM)
-$0.86
52W Low $14.23High $28.00

Volume 0.34M

Average 0.45M

ATTO Net Debt

Total debt minus cash and equivalents; a negative value means the company holds more cash than debt.

Attovia Therapeutics, Inc.NASDAQ: ATTO

Net Debt · Q2 FY2026 · quarter ended Jun 2026

Net debt of -$28.5M in Q2 FY2026

Q2 FY2026 net debt was -$28.5M.

Context

  • Net debt amounted to 22.2% of total assets at the end of Q2 FY2026.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterJun 2026
-$28.5M+26.0% QoQ
Last fiscal yearDec 2025
-$34.93M-14.0% YoY
Net Debt past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year-14.0%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Net Debt history

USD · from the balance sheet

Latest · FY2025
(34.93M) USD
Year-over-year change
-14.0%

Net Debt vs competitors

How ATTO compares with its peers on the latest reported figures

  • Peers report in different currencies, so net debt is compared through growth and share of total assets rather than absolute size.
  • Net debt amounts to 22.2% of total assets for ATTO, versus a peer median of 32.3%.
ATTO Competitors
Net Debt for ATTO and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
ANABAnaptysBio, Inc.Mar 2026$28.89M USD+134.8%—8.8%
ACRSAclaris Therapeutics, Inc.Mar 2026-$26.68M USD+4.3%—13.4%
ALMSAlumis Inc. Common StockJun 2026-$27.28M USD+75.9%—4.9%
ATTOAttovia Therapeutics, Inc.Jun 2026-$28.5M USD——22.2%
CNTBConnect Biopharma Holdings LimitedDec 2025-$37.66M USD+51.8%—67.2%
EVMNEvommune, Inc.Mar 2026-$39.2M USD-120.9%—12.2%
QTTBQ32 Bio Inc.Mar 2026-$39.76M USD+14.8%—62.4%
AGMBAgomAb Therapeutics N.V. American Depositary SharesSep 2025-€128.26M EUR——77.4%
ORKAOruka Therapeutics, Inc.Sep 2026-$188.59M USD-111.1%—15.3%
MLTXMoonLake ImmunotherapeuticsMar 2026-$197.69M USD-0.9%—49.4%
ZURAZura Bio LimitedMar 2026-$225.59M USD-32.3%—98.7%
Peer median (excluding ATTO) —+4.3%—32.3%

Competitors are the stored peer set for ATTO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Attovia Therapeutics, Inc.

NASDAQ:ATTO

Intrinsic Alpha fair value

Locked

Current Price

$15.53

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.